CRYPTOCOCCAL VACCINE

隐球菌疫苗

• 批准号: 3790889
• 负责人: J BENNETT
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3790889
• 关键词: Cryptococcus; cell capsule; drug design /synthesis /production; fungal vaccines; human subject; laboratory mouse; polysaccharides; tetanus toxoid

A vaccine composed of cryptococcal capsular polysaccharide (glucuronoxylomannan, GXM) covalently linked to tetanus toxoid was well tolerated and immunogenic in 25 normal volunteers given 25 mcg of polysaccharide and 25 given 50 mcg. There was no significant difference in the response between the two doses. Repeating the 25 or 50 mcg dose at 6 weeks did not significantly increase either the IgG or IgM antibody concentration. In mice, this vaccine conferred 70-80% protection against infection in mice pretreated either with the vaccine or serum from mice immunized with the vaccine.

隐球菌荚膜多糖疫苗 （葡萄糖醛酸甘露聚糖，GXM）共价连接破伤风类毒素， 耐受性和免疫原性在25名正常志愿者给予25微克 多糖和25给予50微克。 无显著性差异 在两个剂量之间的反应。 重复25或50 mcg剂量 在6周时，IgG或IgM抗体均未显著增加 浓度. 在小鼠中，这种疫苗对以下疾病具有70-80%的保护作用： 用疫苗或小鼠血清预处理的小鼠感染 用疫苗免疫。